Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
DOI: | 10.32385/rpmgf.v37i3.12820 |
Texto Completo: | https://doi.org/10.32385/rpmgf.v37i3.12820 |
Resumo: | Objectives: Gastroesophageal reflux disease is one of the most common gastrointestinal diagnoses. This disorder causes many symptoms and may induce the development of Barret’s esophagus and esophageal adenocarcinoma. Proton pump inhibitors are the most used treatment and, usually, are prescribed for once-daily dosing before breakfast. However, many patients describe night-time symptoms, a period when an increase of basal gastric acid secretion occurs. Therefore, this evidence-based review was performed in order to understand which is the best regimen for proton pump inhibitor intake.Methods: The MeSH words ‘proton pump inhibitors’, ‘gastro-oesophageal reflux’, GERD, and pH were chosen to search for synopses, guidelines, meta-analysis, systematic reviews, and original papers, published after 2008 in the databases MEDLINE, National Guideline Clearinghouse, NHS Evidence, Canadian Medical Association, TRIP Database, The Cochrane Library, DARE and Bandolier in English, French, Spanish and Portuguese. A search in the Índex de Revistas Médicas Portuguesas with the words “inibidores das bombas de protões”, “refluxo gastroesofágico”, DRGE, and pH was also performed. The search retrieves 2,546 articles, from those, three were used in this review.Results: Three prospective studies that evaluate the effects of dosage and/or timing of proton pump inhibitors intake in gastric pH were obtained. These studies indicate that, in patients with predominant night-time symptoms, intake before dinner achieves better results than before breakfast. Additionally, doubling the dose reduces symptoms and the time of pH lower than four.Conclusion: Symptom timing and patient compliance are crucial when choosing the therapeutic regimen. The timing of proton pumps inhibitors intake should be associated with the symptom’s timing; C-level of recommendation. |
id |
RCAP_95b1a12b24b37dd62e074bdb96de1c15 |
---|---|
oai_identifier_str |
oai:ojs.rpmgf.pt:article/12820 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence reviewProton pump inhibitorsGastroesophageal refluxpHObjectives: Gastroesophageal reflux disease is one of the most common gastrointestinal diagnoses. This disorder causes many symptoms and may induce the development of Barret’s esophagus and esophageal adenocarcinoma. Proton pump inhibitors are the most used treatment and, usually, are prescribed for once-daily dosing before breakfast. However, many patients describe night-time symptoms, a period when an increase of basal gastric acid secretion occurs. Therefore, this evidence-based review was performed in order to understand which is the best regimen for proton pump inhibitor intake.Methods: The MeSH words ‘proton pump inhibitors’, ‘gastro-oesophageal reflux’, GERD, and pH were chosen to search for synopses, guidelines, meta-analysis, systematic reviews, and original papers, published after 2008 in the databases MEDLINE, National Guideline Clearinghouse, NHS Evidence, Canadian Medical Association, TRIP Database, The Cochrane Library, DARE and Bandolier in English, French, Spanish and Portuguese. A search in the Índex de Revistas Médicas Portuguesas with the words “inibidores das bombas de protões”, “refluxo gastroesofágico”, DRGE, and pH was also performed. The search retrieves 2,546 articles, from those, three were used in this review.Results: Three prospective studies that evaluate the effects of dosage and/or timing of proton pump inhibitors intake in gastric pH were obtained. These studies indicate that, in patients with predominant night-time symptoms, intake before dinner achieves better results than before breakfast. Additionally, doubling the dose reduces symptoms and the time of pH lower than four.Conclusion: Symptom timing and patient compliance are crucial when choosing the therapeutic regimen. The timing of proton pumps inhibitors intake should be associated with the symptom’s timing; C-level of recommendation.Associação Portuguesa de Medicina Geral e Familiar2021-07-02info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.32385/rpmgf.v37i3.12820https://doi.org/10.32385/rpmgf.v37i3.12820Portuguese Journal of Family Medicine and General Practice; Vol. 37 No. 3 (2021): Revista Portuguesa de Medicina Geral e Familiar; 223-9Revista Portuguesa de Medicina Geral e Familiar; Vol. 37 Núm. 3 (2021): Revista Portuguesa de Medicina Geral e Familiar; 223-9Revista Portuguesa de Medicina Geral e Familiar; Vol. 37 N.º 3 (2021): Revista Portuguesa de Medicina Geral e Familiar; 223-92182-51812182-517310.32385/rpmgf.v37i3reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://rpmgf.pt/ojs/index.php/rpmgf/article/view/12820https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12820/pdfDireitos de Autor (c) 2021 Revista Portuguesa de Medicina Geral e Familiarinfo:eu-repo/semantics/openAccessSilva, Rui JFPinto, Nuno Teles2024-09-17T12:00:23Zoai:ojs.rpmgf.pt:article/12820Portal AgregadorONGhttps://www.rcaap.pt/oai/openairemluisa.alvim@gmail.comopendoar:71602024-09-17T12:00:23Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review |
title |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review |
spellingShingle |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review Silva, Rui JF Proton pump inhibitors Gastroesophageal reflux pH Silva, Rui JF Proton pump inhibitors Gastroesophageal reflux pH |
title_short |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review |
title_full |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review |
title_fullStr |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review |
title_full_unstemmed |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review |
title_sort |
Proton pumps inhibitors in gastroesophageal reflux disease: what is the best regimen? A based evidence review |
author |
Silva, Rui JF |
author_facet |
Silva, Rui JF Silva, Rui JF Pinto, Nuno Teles Pinto, Nuno Teles |
author_role |
author |
author2 |
Pinto, Nuno Teles |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Silva, Rui JF Pinto, Nuno Teles |
dc.subject.por.fl_str_mv |
Proton pump inhibitors Gastroesophageal reflux pH |
topic |
Proton pump inhibitors Gastroesophageal reflux pH |
description |
Objectives: Gastroesophageal reflux disease is one of the most common gastrointestinal diagnoses. This disorder causes many symptoms and may induce the development of Barret’s esophagus and esophageal adenocarcinoma. Proton pump inhibitors are the most used treatment and, usually, are prescribed for once-daily dosing before breakfast. However, many patients describe night-time symptoms, a period when an increase of basal gastric acid secretion occurs. Therefore, this evidence-based review was performed in order to understand which is the best regimen for proton pump inhibitor intake.Methods: The MeSH words ‘proton pump inhibitors’, ‘gastro-oesophageal reflux’, GERD, and pH were chosen to search for synopses, guidelines, meta-analysis, systematic reviews, and original papers, published after 2008 in the databases MEDLINE, National Guideline Clearinghouse, NHS Evidence, Canadian Medical Association, TRIP Database, The Cochrane Library, DARE and Bandolier in English, French, Spanish and Portuguese. A search in the Índex de Revistas Médicas Portuguesas with the words “inibidores das bombas de protões”, “refluxo gastroesofágico”, DRGE, and pH was also performed. The search retrieves 2,546 articles, from those, three were used in this review.Results: Three prospective studies that evaluate the effects of dosage and/or timing of proton pump inhibitors intake in gastric pH were obtained. These studies indicate that, in patients with predominant night-time symptoms, intake before dinner achieves better results than before breakfast. Additionally, doubling the dose reduces symptoms and the time of pH lower than four.Conclusion: Symptom timing and patient compliance are crucial when choosing the therapeutic regimen. The timing of proton pumps inhibitors intake should be associated with the symptom’s timing; C-level of recommendation. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-07-02 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.32385/rpmgf.v37i3.12820 https://doi.org/10.32385/rpmgf.v37i3.12820 |
url |
https://doi.org/10.32385/rpmgf.v37i3.12820 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12820 https://rpmgf.pt/ojs/index.php/rpmgf/article/view/12820/pdf |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2021 Revista Portuguesa de Medicina Geral e Familiar info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2021 Revista Portuguesa de Medicina Geral e Familiar |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Associação Portuguesa de Medicina Geral e Familiar |
publisher.none.fl_str_mv |
Associação Portuguesa de Medicina Geral e Familiar |
dc.source.none.fl_str_mv |
Portuguese Journal of Family Medicine and General Practice; Vol. 37 No. 3 (2021): Revista Portuguesa de Medicina Geral e Familiar; 223-9 Revista Portuguesa de Medicina Geral e Familiar; Vol. 37 Núm. 3 (2021): Revista Portuguesa de Medicina Geral e Familiar; 223-9 Revista Portuguesa de Medicina Geral e Familiar; Vol. 37 N.º 3 (2021): Revista Portuguesa de Medicina Geral e Familiar; 223-9 2182-5181 2182-5173 10.32385/rpmgf.v37i3 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
mluisa.alvim@gmail.com |
_version_ |
1822181851896217600 |
dc.identifier.doi.none.fl_str_mv |
10.32385/rpmgf.v37i3.12820 |